TransThera's Biliary Tract Cancer Drug Included in Clinical Oncology Society's Guidelines

MT Newswires Live09-18

TransThera Sciences (Nanjing)'s (HKG:2617) Yochanra has been included in the Chinese Society of Clinical Oncology's guidelines for the diagnosis and treatment of biliary tract cancers.

The inclusion is for the drug as a Class II recommendation Class 2A for the treatment of advanced biliary tract cancers, a Friday bourse filing showed.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment